Chapter title |
Structure-Based Drug Discovery
|
---|---|
Chapter number | 14 |
Book title |
Structure-Based Drug Discovery
|
Published in |
Methods in molecular biology, January 2012
|
DOI | 10.1007/978-1-61779-520-6_14 |
Pubmed ID | |
Book ISBNs |
978-1-61779-519-0, 978-1-61779-520-6
|
Authors |
Gary L. Gilliland, Jinquan Luo, Omid Vafa, Juan Carlos Almagro, Gilliland, Gary L., Luo, Jinquan, Vafa, Omid, Almagro, Juan Carlos |
Abstract |
Antibodies make up the largest, growing segment of protein therapeutics in the pharmaceutical and biotechnology industries. The development or engineering of therapeutic antibodies is based to a large extent on our knowledge of antibody structure and requires sophisticated methods that continue to evolve. In this chapter, after a review of what is known about the structure and functional properties of antibodies, the current, state-of-the-art antibody engineering methods are described. These methods include antibody humanization, antigen-affinity optimization, Fc engineering for modulated effector function and extended half-life, and engineering for improved stability and biophysical properties. X-ray crystallographic structures of antibody fragments and their complexes can play a critical role in guiding and, in some cases, accelerating these processes. These approaches represent guidelines for developing antibody therapeutics with the desired affinity, effector function, and biophysical properties. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 3% |
Unknown | 38 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 12 | 31% |
Student > Master | 4 | 10% |
Student > Bachelor | 4 | 10% |
Other | 3 | 8% |
Student > Ph. D. Student | 3 | 8% |
Other | 7 | 18% |
Unknown | 6 | 15% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 12 | 31% |
Biochemistry, Genetics and Molecular Biology | 10 | 26% |
Chemical Engineering | 2 | 5% |
Computer Science | 2 | 5% |
Medicine and Dentistry | 2 | 5% |
Other | 3 | 8% |
Unknown | 8 | 21% |